Merck, Schering swing to 4Q profit

Merck and Schering-Plough both reported surprisingly strong profits for the fourth quarter in spite of a steep decline in sales of Vytorin and Zetia, the cholesterol drugs they market together.

Merck posted $1.64 billion in profits, or 78 cents per share; that compares with a net loss of almost that much--$1.63 billion--during the same period last year. That's when Merck took a multibillion-dollar charge for its big Vioxx settlement. Without that charge and another restructuring charge posted this quarter, the drugmaker would have boosted EPS to 87 cents from 80 cents a year ago, the Wall Street Journal figures.

Schering reported net income of $480 million, or 27 cents per share. For the fourth quarter of last year, the company posted a $3.36 billion loss because of charges related to its buyout of Organon BioSciences. On an adjusted basis, earnings grew to 39 cents per share from 27 cents the same period a year ago.

Combined sales of Vytorin and Zetia fell off by 26 percent during the period, to $1.1 billion, despite a new government-sponsored study that found Zetia therapy delivered benefits against progression of cardiovascular disease. Meanwhile, sales of Merck's human papillomavirus vaccine fell by 16 percent, a trend the company hopes to reverse with new indications for the shot. Overall, Merck's sales dropped 3 percent to about $6 billion.

Schering, on the other hand, saw a 17 percent rise in net sales, to $4.35 billion, on its buyout of Organon. Among the individual drugs posting gains were anti-inflammatory Remicade (8 percent), allergy med Nasonex (3 percent), and cancer treatment Temodar (4 percent).

- read the WSJ story
- get more on Merck from CNBC

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.